Loading clinical trials...
Loading clinical trials...
This is a research study to look at the ways in which a treatment called INGN241 can kill melanoma cells or help the patient's immune system kill melanoma cells.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Introgen Therapeutics
Collaborators
NCT05614739 · Urinary Bladder Neoplasms, Neoplasm Metastasis, and more
NCT06150664 · Non Small Cell Lung Cancer, Triple Negative Breast Cancer, and more
NCT07174336 · Breast Neoplasms, Neoplasm Metastasis
NCT06961006 · Malignant Melanoma
NCT07213804 · Ovarian Neoplasms, Fallopian Tube Neoplasms, and more
University of Texas MD Anderson Cancer Center
Houston, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions